Kelun-Biotech reports interim results for the first half of 2026

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. released its unaudited consolidated financial results for the period ending June 30, 2026, on August 17, 2026. The announcement pertains to the first half of the company's fiscal year.

The company, trading under stock code 6990.HK, has submitted its consolidated figures for review. Specific financial metrics from the reporting period were not detailed in the initial statement.

Kelun-Biotech operates in the biopharmaceutical industry, a sector focused on the research and development of new medicines. This interim report provides an overview of the company's operational and financial standing during the specified timeframe.

Further details regarding the company's performance and strategic outlook are expected in subsequent publications. These results are intended to update shareholders and stakeholders on Kelun-Biotech's progress.